Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 103-110 , May 2006

GIST: Particular aspects related to cell cultures, xenografts, and cytogenetics

  • José Antonio López-Guerrero, PhD

      Affiliations

    • Unit of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
    • ,
  • Rosa Noguera, MD

      Affiliations

    • Department of Pathology, University of Valencia, Valencia, Spain.
    • ,
  • Antonio Llombart-Bosch, MD

      Affiliations

    • Department of Pathology, University of Valencia, Valencia, Spain.
    • Corresponding Author InformationAddress reprint requests and correspondence: Antonio Llombart-Bosch, MD, Department of Pathology, University of Valencia, Avda. Blasco Ibañez, 17, Valencia, Spain.

References 

  1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580
  2. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–1056
  3. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24:25–35
  4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–3825
  5. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269
  6. Sakurai S, Fukasawa T, Chong JM, et al. Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumor and interstitial cells of Cajal. Am J Pathol. 1999;154:23–28
  7. Thuneberg L. Interstitial cells of Cajal: intestinal pacemaker cells?. Adv Anat Embryol Cell Biol. 1982;71:1–130
  8. Jeng YM, Mao TL, Hsu WM, et al. Congenital interstitial cell of cajal hyperplasia with neuronal intestinal dysplasia. Am J Surg Pathol. 2000;24:1568–1572
  9. Kluppel M, Huizinga JD, Malysz J, et al. Developmental origin and Kit-dependent development of the interstitial cells of cajal in the mammalian small intestine. Dev Dyn. 1998;211:60–71
  10. Sanders KM. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology. 1996;111:492–515
  11. Thomsen L, Robinson TL, Lee JC, et al. Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med. 1998;4:848–851
  12. Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol. 2001;32:578–582
  13. Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A. 2003;100:6706–6711
  14. Mukaisho K, Miwa K, Totsuka Y, et al. Induction of gastric GIST in rat and establishment of GIST cell line. Cancer Lett. 2006;231:295–303
  15. Rossi S, Ou W, Tang D, et al. Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol. 2006;209:369–375
  16. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20:5054–5058
  17. Noma K, Naomoto Y, Gunduz M, et al. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. Oncol Rep. 2005;14:645–650
  18. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349
  19. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357–5364
  20. Prenen H, Guetens G, de Boeck G, et al. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology. 2006;77:11–16
  21. Llombart-Bosch A, Carda C, Boix J, et al. Value of nude mice xenografts in the expression of cell heterogeneity of human sarcomas of bone and soft tissue. Pathol Res Pract. 1988;183:683–692
  22. Subramaniam MM, Navarro S, Pellin A, et al. Tissue microarray profiling of primary and xenotransplanted synovial sarcomas demonstrates the immunophenotypic similarities existing between SYT-SSX fusion gene confirmed, biphasic and monophasic fibrous variants. Virchows Arch. 2006;449:435–437
  23. Llombart-Bosch A, Lopez-Guerrero JA, Carda Batalla C, et al. Structural basis of tumoral angiogenesis. Adv Exp Med Biol. 2003;532:69–89
  24. Taguchi T, Sonobe H, Toyonaga S, et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest. 2002;82:663–665
  25. Prenen H, Deroose C, Vermaelen P, et al. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res. 2006;26:1247–1252
  26. Cullinane C, Dorow DS, Kansara M, et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res. 2005;65:9633–9636
  27. Rubin BP, Antonescu CR, Scott-Browne JP, et al. A knock-in mouse model of gastrointestinal stromal tumor harboring kit K641E. Cancer Res. 2005;65:6631–6639
  28. Bai CG, Liu XH, Xie Q, et al. A novel gain of function mutant in C-kit gene and its tumorigenesis in nude mice. World J Gastroenterol. 2005;11:7104–7108
  29. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005;23:6190–6198
  30. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898–3905
  31. el-Rifai W, Sarlomo-Rikala M, Miettinen M, et al. DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res. 1996;56:3230–3233
  32. El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res. 2000;60:3899–3903
  33. Miettinen M, Monihan JM, Sarlomo-Rikala M, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23:1109–1118
  34. Reith JD, Goldblum JR, Lyles RH, et al. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000;13:577–585
  35. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: gastrointestinal stromal tumors. Cancer Genet Cytogenet. 2002;135:1–22
  36. Breiner JA, Meis-Kindblom J, Kindblom LG, et al. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). Cancer Genet Cytogenet. 2000;120:111–116
  37. El-Rifai W, Sarlomo-Rikala M, Andersson LC, et al. High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. Genes Chromosomes Cancer. 2000;27:387–391
  38. Marci V, Casorzo L, Sarotto I, et al. Gastrointestinal stromal tumor, uncommitted type, with monosomies 14 and 22 as the only chromosomal abnormalities. Cancer Genet Cytogenet. 1998;102:135–138
  39. Bergmann F, Gunawan B, Hermanns B, et al. Cytogenetic and morphologic characteristics of gastrointestinal stromal tumors (Recurrent rearrangement of chromosome 1 and losses of chromosomes 14 and 22 as common anomalies). Verh Dtsch Ges Pathol. 1998;82:275–278
  40. Saunders AL, Meloni AM, Chen Z, et al. Two cases of low-grade gastric leiomyosarcoma with monosomy 14 as the only change. Cancer Genet Cytogenet. 1996;90:184–185
  41. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet. 2001;128:24–30
  42. Fukasawa T, Chong JM, Sakurai S, et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res. 2000;91:1241–1249
  43. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728–734
  44. Sarlomo-Rikala M, El-Rifai W, Lahtinen T, et al. Different patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwannomas. Hum Pathol. 1998;29:476–481
  45. O’Leary T, Ernst S, Przygodzki R, et al. Loss of heterozygosity at 1p36 predicts poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest. 1999;79:1461–1467
  46. Kallioniemi OP, Kallioniemi A, Piper J, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994;10:231–243
  47. Zielenska M, Marrano P, Thorner P, et al. High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenet Genome Res. 2004;107:77–82
  48. Knuutila S, Armengol G, Bjorkqvist AM, et al. Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet. 1998;100:25–30
  49. Pollack JR, Perou CM, Alizadeh AA, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999;23:41–46
  50. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using compartaive genomic hybridization to microarrays. Nat Genet. 1998;20:207–211
  51. Brennan C, Zhang Y, Leo C, et al. High-resolution global profiling of genomic alterations with long oligo-nucleotide microarray. Cancer Res. 2004;64:4744–4748
  52. Aguirre AJ, Brennan C, Bailey G, et al. High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A. 2004;101:9067–9072
  53. Maertens O, Prenen H, Debiec-Rychter M, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet. 2006;15:1015–1023
  54. Fletcher CD. Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol. 2002;33:455
  55. Gunawan B, Bergmann F, Hoer J, et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol. 2002;33:316–321
  56. Kim NG, Kim JJ, Ahn JY, et al. Putative chromosomal deletions on 9P, 9Q and 22Q occur preferentially in malignant gastrointestinal stromal tumors. Int J Cancer. 2000;85:633–638
  57. Sabah M, Cummins R, Leader M, et al. Loss of heterozigosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumor. Mod Pathol. 2004;17:1364–1371
  58. Perrone F, Tamborini E, Dagrada GP, et al. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer. 2005;104:159–169
  59. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707
  60. Sharpless EN, DePinho RA. The INK4/ARF locus and its two gene products. Curr Opin Genet Dev. 1999;9:22–30
  61. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677
  62. Ricci R, Arena V, Castri F, et al. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol. 2004;122:35–43
  63. Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4A alterations in gastrointestinal stromal tumors. J Clin Oncol. 2003;21:1688–1697
  64. Yamashita K, Igarashi H, Kitayama Y, et al. Chromosomal numerical abnormality profiles of gastrointestinal stromal tumors. Jpn J Clin Oncol. 2006;36:85–92
  65. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270–279
  66. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–4190

PII: S0740-2570(06)00140-7

doi: 10.1053/j.semdp.2006.08.004

Seminars in Diagnostic Pathology
Volume 23, Issue 2 , Pages 103-110 , May 2006

Article Tools

* Image Usage & Resolution